

Catalog# BP- 50523

Ramucirumab Biosimilar (Human VEGFR2 Monoclonal Antibody)

Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.

Kinase inserts domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of differentiation 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothelial growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic variant affects VEGFR-2 phosphorylation and has been found to associate with microvessel density in NSCLC.

Product Details	
CAS No.	947687-13-0
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Ramucirumab Biosimilar
Conjugate	Unconjugated
Immunogen	The human VEGFR2 (KDR)
Purity	>95%
Molecular Weight	144.56 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.